{"id":"hpv-16-18-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain or erythema"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The HPV-16/18 vaccine is a prophylactic immunization that trains the body's adaptive immune response to recognize and neutralize HPV-16 and HPV-18 viral particles before infection occurs. By generating both humoral (antibody) and cell-mediated immune responses, the vaccine prevents persistent infection with these high-risk HPV types, which are responsible for the majority of cervical cancers and other HPV-associated malignancies.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types 16 and 18, preventing infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:38.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV-16 and HPV-18"},{"name":"Prevention of other HPV-16/18-associated cancers (anal, oropharyngeal, vulvar, vaginal)"}]},"trialDetails":[{"nctId":"NCT05985681","phase":"PHASE1","title":"Testing RG1-VLP Vaccine to Prevent HPV-related Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-27","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":18},{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT06210854","phase":"PHASE2","title":"Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05-01","conditions":"HPV Infection","enrollment":48},{"nctId":"NCT05334706","phase":"PHASE4","title":"A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)","status":"RECRUITING","sponsor":"Miquel Angel Pavon Ribas","startDate":"2022-09-13","conditions":"Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV","enrollment":69},{"nctId":"NCT07303751","phase":"PHASE2","title":"Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","status":"NOT_YET_RECRUITING","sponsor":"Institut d'Investigació Biomèdica de Bellvitge","startDate":"2026-02-01","conditions":"HPV, High-risk HPV (Any Strain), Human Papillomavirus (HPV) Infections","enrollment":80},{"nctId":"NCT03309033","phase":"","title":"Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-02","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm","enrollment":991},{"nctId":"NCT06411938","phase":"NA","title":"A Cervical Cancer Prevention Program in Kenya","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indiana University","startDate":"2024-04-02","conditions":"Cervical Cancer Prevention, Cervical Cancer","enrollment":2300},{"nctId":"NCT07240220","phase":"NA","title":"The Mother-Daughter Project: Merck-4","status":"NOT_YET_RECRUITING","sponsor":"Indiana University","startDate":"2026-02-01","conditions":"Cervical Dysplasia","enrollment":2500},{"nctId":"NCT05247853","phase":"","title":"HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2021-11-03","conditions":"Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus","enrollment":3127},{"nctId":"NCT05996523","phase":"PHASE2","title":"Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-07","conditions":"Oropharyngeal Squamous Cell Carcinoma (SCC)","enrollment":16},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT05341284","phase":"","title":"Impact of HPV Vaccination on HPV Infection and Cervical Related Disease Burden in Real-World Settings (HPV-RWS)","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2022-08-01","conditions":"HPV Infection, Cervical Disease","enrollment":""},{"nctId":"NCT03728881","phase":"PHASE3","title":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":1240},{"nctId":"NCT00092534","phase":"PHASE3","title":"Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-14","conditions":"Cervical Cancer, Genital Warts","enrollment":12167},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection","enrollment":2188},{"nctId":"NCT03444376","phase":"PHASE1, PHASE2","title":"The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer","status":"COMPLETED","sponsor":"Genexine, Inc.","startDate":"2018-06-19","conditions":"Cervical Cancer","enrollment":65},{"nctId":"NCT07092007","phase":"NA","title":"NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer","status":"RECRUITING","sponsor":"Newish Technology (Beijing) Co., Ltd.","startDate":"2024-06-05","conditions":"Intraepithelial Neoplasia, Cervical Cancer","enrollment":18},{"nctId":"NCT03603808","phase":"PHASE2","title":"VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2018-09-21","conditions":"Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity","enrollment":35},{"nctId":"NCT07047989","phase":"PHASE1","title":"NWRD09 for HPV-16 Related Cervical HSIL","status":"RECRUITING","sponsor":"Newish Biotech (Wuxi) Co., Ltd.","startDate":"2025-06-12","conditions":"High-grade Squamous Intraepithelial Lesion (HSIL)","enrollment":9},{"nctId":"NCT03610581","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-09-27","conditions":"Human Papillomavirus Infections","enrollment":9},{"nctId":"NCT06797986","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.","status":"NOT_YET_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2025-03","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06776055","phase":"","title":"Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2023-03-27","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":5372},{"nctId":"NCT06276101","phase":"PHASE1","title":"NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL","status":"UNKNOWN","sponsor":"Newish Technology (Beijing) Co., Ltd.","startDate":"2024-01-25","conditions":"High-grade Squamous Intraepithelial Lesion (HSIL)","enrollment":9},{"nctId":"NCT06273553","phase":"PHASE1, PHASE2","title":"A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3","status":"NOT_YET_RECRUITING","sponsor":"RinuaGene Biotechnology Co., Ltd.","startDate":"2024-03","conditions":"Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Type 16 Infection","enrollment":39},{"nctId":"NCT04590521","phase":"PHASE4","title":"HPV Vaccine Immunity in High-risk Women","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-09-14","conditions":"HPV Infection","enrollment":63},{"nctId":"NCT02740790","phase":"PHASE2","title":"Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females","status":"COMPLETED","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2013-09","conditions":"Human Papillomavirus","enrollment":1200},{"nctId":"NCT02740777","phase":"PHASE2","title":"Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females","status":"COMPLETED","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2016-02","conditions":"Human Papillomavirus, Cervical Intraepithelial Neoplasia, Persistent Infection","enrollment":900},{"nctId":"NCT03671369","phase":"","title":"A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-10-02","conditions":"Neoplasms, Rectal","enrollment":670},{"nctId":"NCT05045755","phase":"","title":"The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-04-13","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":1339},{"nctId":"NCT04704908","phase":"","title":"Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-02-06","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":979},{"nctId":"NCT04969445","phase":"","title":"The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-03-30","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":647},{"nctId":"NCT02733068","phase":"PHASE3","title":"A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.","status":"COMPLETED","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2014-11-02","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Cervical Intraepithelial Neoplasia","enrollment":12000},{"nctId":"NCT05173324","phase":"PHASE3","title":"Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial","status":"NOT_YET_RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2023-02-01","conditions":"HPV Infection","enrollment":8000},{"nctId":"NCT05426148","phase":"PHASE4","title":"Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2020-05-01","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":540},{"nctId":"NCT05415345","phase":"PHASE4","title":"Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin","status":"UNKNOWN","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2021-10-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Hepatitis E Virus Infection","enrollment":480},{"nctId":"NCT05279248","phase":"PHASE4","title":"The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-08-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles","enrollment":300},{"nctId":"NCT00604175","phase":"PHASE2","title":"Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-02","conditions":"HIV Infections, Sexually Transmitted Diseases","enrollment":319},{"nctId":"NCT03438006","phase":"","title":"A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-05-31","conditions":"Cervical Intraepithelial Neoplasia","enrollment":3016},{"nctId":"NCT04800978","phase":"PHASE2","title":"Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-06-14","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT03355820","phase":"PHASE3","title":"A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-02-28","conditions":"Cervical Intraepithelial Neoplasia","enrollment":228},{"nctId":"NCT00481767","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-01","conditions":"Human Papillomavirus (HPV) Infection","enrollment":676},{"nctId":"NCT03105856","phase":"PHASE4","title":"FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2017-01-03","conditions":"Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma","enrollment":3000},{"nctId":"NCT01263327","phase":"PHASE1","title":"Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2010-12","conditions":"Cervical Cancer","enrollment":38},{"nctId":"NCT01381575","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-29","conditions":"Infections, Papillomavirus","enrollment":1447},{"nctId":"NCT03747770","phase":"NA","title":"Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2018-12-17","conditions":"Healthy","enrollment":18000},{"nctId":"NCT01627561","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Infections, Papillomavirus","enrollment":148},{"nctId":"NCT01735006","phase":"PHASE3","title":"Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2012-11-22","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":7372},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT00250276","phase":"PHASE3","title":"Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10-28","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":798},{"nctId":"NCT00294047","phase":"PHASE3","title":"Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-16","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":5752},{"nctId":"NCT00231413","phase":"PHASE2","title":"Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-04","conditions":"Infections, Papillomavirus","enrollment":383},{"nctId":"NCT00196937","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10-07","conditions":"Infections, Papillomavirus","enrollment":667},{"nctId":"NCT01462357","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-21","conditions":"Infections, Papillomavirus","enrollment":1079},{"nctId":"NCT00730847","phase":"PHASE4","title":"A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2008-09-17","conditions":"Human Papillomavirus Infection Leading to Cervical Cancer","enrollment":743},{"nctId":"NCT04022148","phase":"","title":"The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years","status":"UNKNOWN","sponsor":"University of Fukui","startDate":"2019-08-01","conditions":"Cancer of Cervix, Vaccinia","enrollment":2800},{"nctId":"NCT03870113","phase":"PHASE1","title":"DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2019-04-01","conditions":"Cervical Intraepithelial Neoplasia","enrollment":80},{"nctId":"NCT00128661","phase":"PHASE3","title":"Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-30","conditions":"Cervical Cancer, Precancerous Condition","enrollment":7466},{"nctId":"NCT02128126","phase":"PHASE1, PHASE2","title":"Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"ISA Pharmaceuticals","startDate":"2013-09","conditions":"Cervical Cancer","enrollment":93},{"nctId":"NCT03206255","phase":"","title":"Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls","status":"COMPLETED","sponsor":"Jun Zhang","startDate":"2017-07-01","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":940},{"nctId":"NCT00309166","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-05","conditions":"Infections, Papillomavirus","enrollment":270},{"nctId":"NCT01304524","phase":"PHASE2","title":"A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2011-04","conditions":"Cervical Intraepithelial Neoplasia","enrollment":167},{"nctId":"NCT00316693","phase":"PHASE2","title":"Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-26","conditions":"Infections, Papillomavirus","enrollment":1046},{"nctId":"NCT00492544","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Papillomavirus","enrollment":100},{"nctId":"NCT00122681","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05-06","conditions":"Infections, Papillomavirus","enrollment":18729},{"nctId":"NCT00578227","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-15","conditions":"Infections, Papillomavirus","enrollment":814},{"nctId":"NCT02562508","phase":"PHASE3","title":"A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls","status":"COMPLETED","sponsor":"Jun Zhang","startDate":"2015-12-05","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":979},{"nctId":"NCT01101542","phase":"","title":"Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Papillomavirus","enrollment":3091},{"nctId":"NCT00549900","phase":"PHASE1","title":"A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-02","conditions":"Infections, Papillomavirus","enrollment":30},{"nctId":"NCT00345878","phase":"PHASE3","title":"Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":"Infections, Papillomavirus","enrollment":271},{"nctId":"NCT00485732","phase":"PHASE3","title":"A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-11","conditions":"Infections, Papillomavirus","enrollment":225},{"nctId":"NCT00344032","phase":"PHASE3","title":"Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07-28","conditions":"Infections, Papillomavirus","enrollment":354},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT01520272","phase":"","title":"HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-01-02","conditions":"HPV16 Anitbody Levels Post Vaccination, HPV18 Antibody Levels Post Vaccination","enrollment":376},{"nctId":"NCT02411019","phase":"","title":"Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation","status":"UNKNOWN","sponsor":"Genexine, Inc.","startDate":"2015-03","conditions":"Cervical Intraepithelial Neoplasia 3","enrollment":67},{"nctId":"NCT03206138","phase":"NA","title":"Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2017-05-30","conditions":"Cervical Intraepithelial Neoplasia 3","enrollment":50},{"nctId":"NCT00337818","phase":"PHASE3","title":"Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia","enrollment":770},{"nctId":"NCT00196924","phase":"PHASE3","title":"Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06","conditions":"Infections, Papillomavirus","enrollment":2067},{"nctId":"NCT00092482","phase":"PHASE3","title":"Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-28","conditions":"Cervical Cancer, Genital Warts","enrollment":3882},{"nctId":"NCT00456807","phase":"PHASE3","title":"Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Infections, Papillomavirus","enrollment":100},{"nctId":"NCT02689726","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL","status":"TERMINATED","sponsor":"Genticel","startDate":"2015-08","conditions":"HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL","enrollment":13},{"nctId":"NCT01957878","phase":"PHASE2","title":"Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL","status":"COMPLETED","sponsor":"Genticel","startDate":"2013-12","conditions":"Genital Infection Viral, HUMAN PAPILLOMA VIRUS","enrollment":239},{"nctId":"NCT00306241","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Infections, Papillomavirus","enrollment":300},{"nctId":"NCT00120848","phase":"PHASE2","title":"Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Infections, Papillomavirus","enrollment":776},{"nctId":"NCT00290277","phase":"PHASE3","title":"Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Infections, Papillomavirus","enrollment":300},{"nctId":"NCT00693966","phase":"PHASE2","title":"Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-10","conditions":"Infections, Papillomavirus","enrollment":210},{"nctId":"NCT00693615","phase":"PHASE2","title":"Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-10","conditions":"Infections, Papillomavirus","enrollment":60},{"nctId":"NCT00689741","phase":"PHASE2","title":"Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-01","conditions":"Infections, Papillomavirus","enrollment":1113},{"nctId":"NCT00169494","phase":"PHASE3","title":"Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-09","conditions":"Infections, Papillomavirus","enrollment":770},{"nctId":"NCT01356823","phase":"PHASE2","title":"Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2011-03","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer","enrollment":1600},{"nctId":"NCT00365378","phase":"PHASE2","title":"Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-09","conditions":"HPV 16 Infection","enrollment":2409},{"nctId":"NCT01096134","phase":"NA","title":"Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2011-01","conditions":"Cervical Cancer","enrollment":8000},{"nctId":"NCT00092521","phase":"PHASE3","title":"Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12","conditions":"Cervical Cancer, Genital Warts","enrollment":5759},{"nctId":"NCT02100618","phase":"PHASE3","title":"Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-01","conditions":"Infections, Papillomavirus","enrollment":""},{"nctId":"NCT01551537","phase":"","title":"Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Human Papillomavirus Infection","enrollment":""},{"nctId":"NCT00316706","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Cervical Intraepithelial Neoplasia, Papillomavirus Infection","enrollment":1245},{"nctId":"NCT00002916","phase":"PHASE2","title":"Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1996-11","conditions":"Cervical Cancer","enrollment":44},{"nctId":"NCT01548118","phase":"PHASE1","title":"Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2012-02","conditions":"Human Papillomavirus","enrollment":160},{"nctId":"NCT01512784","phase":"PHASE3","title":"Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2011-10","conditions":"HPV, HIV","enrollment":100},{"nctId":"NCT00949572","phase":"NA","title":"Measuring Responses to Sublingual Antigens","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2009-09","conditions":"Sexually Transmitted Diseases, Viral","enrollment":18},{"nctId":"NCT00263744","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"1999-11","conditions":"Healthy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":140,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HPV-16/18 vaccine","genericName":"HPV-16/18 vaccine","companyName":"Shanghai Zerun Biotechnology Co.,Ltd","companyId":"shanghai-zerun-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types 16 and 18, preventing infection and associated cancers. Used for Prevention of cervical cancer caused by HPV-16 and HPV-18, Prevention of other HPV-16/18-associated cancers (anal, oropharyngeal, vulvar, vaginal).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}